<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: : To review the literature on targeted therapy for orbital and periocular <z:hpo ids='HP_0002671'>basal cell carcinoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BCC</z:e>) and cutaneous <z:hpo ids='HP_0002860'>squamous cell carcinoma</z:hpo> (<z:mp ids='MP_0004207'>SCC</z:mp>) and provide examples of patients recently treated with such therapy </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: : The authors reviewed the literature on clinical results of targeted therapy and the molecular basis for targeted therapy in orbital and periocular <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BCC</z:e> and cutaneous <z:mp ids='MP_0004207'>SCC</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>The authors also present representative cases from their practice </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: : Mutation in the patched 1 gene (PTCH1) has been implicated in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BCC</z:e>, and overexpression of epidermal growth factor receptor (EGFR) has been shown in <z:mp ids='MP_0004207'>SCC</z:mp> </plain></SENT>
<SENT sid="4" pm="."><plain>Vismodegib, an inhibitor of smoothened, which is activated upon binding of hedgehog to Ptc, has been shown to significantly decrease <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BCC</z:e> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> size or even produce complete resolution, especially in cases of <z:hpo ids='HP_0002671'>basal cell nevus</z:hpo> syndrome </plain></SENT>
<SENT sid="5" pm="."><plain>Similarly, EGFR inhibitors have been shown to significantly decrease <z:mp ids='MP_0004207'>SCC</z:mp> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> size in cases of locally advanced and <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastatic disease</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>The authors describe successful outcomes after vismodegib treatment in a patient with <z:hpo ids='HP_0002671'>basal cell nevus</z:hpo> syndrome with numerous bulky lesions of the eyelid and periocular region and <z:chebi fb="0" ids="114785">erlotinib</z:chebi> (EGFR inhibitor) treatment in a patient with <z:mp ids='MP_0004207'>SCC</z:mp> who was deemed not to be a good surgical candidate because of advanced <z:mp ids='MP_0004207'>SCC</z:mp> of the orbit with <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> to the regional lymph nodes, advanced age, and multiple medical comorbidities </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: : Targeted therapy using hedgehog pathway and EGFR inhibitors shows significant promise in treatment of orbital and periocular <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BCC</z:e> and cutaneous <z:mp ids='MP_0004207'>SCC</z:mp>, respectively </plain></SENT>
<SENT sid="8" pm="."><plain>Such targeted therapy may be appropriate for patients who are not good candidates for surgery </plain></SENT>
</text></document>